Zhang Yunwei
King & Wood Mallesons
Articles
Commercialising therapeutic drugs in China: cross-border contract manufacture in doubt
China - August 3 2022 Since the introduction of a nationwide Marketing Authorization Holder (MAH) system in 2019, licenses have linked directly to therapeutic products…
China’s healthcare industry is booming. What investment opportunities does it bring?
China - August 3 2022 The health sector in China is experiencing unprecedented growth. A variety of factors, including extended life expectancy, an Aging population and…
如何理解“第三方平台提供者不得直接参与药品网络销售活动”
Asia-Pacific, China - June 27 2022 日前，在《药品管理法实施条例（修订草案征求意见稿）》（“征求意见稿”）发布一个多月以后，“国家拟禁第三方平台直接参与药品网售”的消息突然引发关注冲上热搜，并一度导致相关公司股价大跌。有媒体称该规定将对医药电商第三方平台公司的业务造成较大影响。针对这一说法，本文拟就该规定对医药电商第三方平台（“第三…
Cross-Border CMO Structure Still in Doubt under China MAH Rules
China - June 23 2022 Since the introduction of a nationwide Marketing Authorization Holder (MAH) system in 2019, licenses have linked directly to therapeutic products…
China relaxes rules on lab-developed tests - but uncertainties remain
China - May 19 2022 New regulations in China designed to encourage innovation in clinical trials have made it easier to test human samples in a lab setting. Lab tests on…
